According to a recent LinkedIn post from Truveta, the company’s Truveta Research unit is featured in an Associated Press article examining use of the Wegovy pill, an oral semaglutide therapy. The post indicates that Truveta’s real‑world data analysis found that 36.1% of patients starting oral semaglutide had not previously used GLP‑1 therapies, suggesting significant uptake among new patients.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The LinkedIn post highlights that these findings may point to expanded access to treatment and an evolving pattern of adoption across clinical practice, including increased prescribing by primary care providers. For investors, this visibility in a major media outlet and demonstration of granular, real‑world insights could enhance Truveta’s positioning as a valuable data and analytics partner to life sciences and healthcare stakeholders, potentially supporting demand for its research platform and services.